Novo Nordisk, Pfizer, GSK drugs likely to be in 2027 Medicare negotiations
Most drugs already discounted, limited impact seen on Big Pharma
Analysts expect price cuts to have bigger bite starting in 2028

NEW YORK, Aug 23 Reuters Now that the U.S. government has negotiated prices for some Medicare program drugs effective in 2026, Wall Street analysts are betting on a 2027 list that will include Novo Nordisk39;s blockbuster Ozempic for diabetes and have a limited impact on Big Pharma.

Other possible 2027 candidates include Pfizer39;s cancer drugs Ibrance and Xtandi, GSK39;s asthma and chronic obstructive pulmonary disease COPD treatment Trelegy Ellipta, Teva39;s Huntington39;s disease treatment Austedo and Abbvie39;s irritable bowel syndrome drug Linzess, according to five analysts as well as researchers and company executives.

The drugs, which have been on the market since at least 2017, are among those that the Medicare health program spends the most on for people aged 65 and older or with disabilities. Regulators are due to announce the list of 15 more drugs by February of 2025.

Under President Joe Biden39;s signature Inflation Reduction Act IRA, prices for 10 highly popular prescription drugs used by Medicare will be cut by 38 to 79 in 2026. The industry has fought the negotiation program, saying it will stifle innovation.

Government researchers predict that the use of diabetes drug Ozempic for weight loss would raise the U.S. deficit over the next 10 years at…